Therapeutic potential of host defense peptides in antibiotic-resistant infections

Current Pharmaceutical Design

Volumn 18, Issue 6, 2012, Pages 807-819

  Afacan, Nicole J ^a   Yeung, Amy T Y ^a   Pena, Olga M ^a   Hancock, Robert E W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Chemoattractant; Host defense peptide; Immunity; Immunomodulatory; Infection; Inflammation; Multi drug resistant bacteria; Therapeutic

Indexed keywords

ALPHA DEFENSIN; AMINOGLYCOSIDE; BETA LACTAM; CHEMOTACTIC FACTOR; CHLORAMPHENICOL; DELMITIDE; DNA TOPOISOMERASE; ENDOTOXIN; HOST RESISTANCE PEPTIDE; INDOLICIDIN; INTERLEUKIN 8; ISEGANAN; LINCOSAMIDE; LIPOTEICHOIC ACID; MACROLIDE; MITOGEN ACTIVATED PROTEIN KINASE 3; OMIGANAN; OPEBACAN; PEXIGANAN; POLYKETIDE; QUINOLONE; SULFANILAMIDE DERIVATIVE; TALACTOFERRIN; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; CELL DIFFERENTIATION; CHROMOSOME 8P; DRUG DESIGN; ENTEROCOCCUS FAECALIS; HOSPITAL INFECTION; HOST RESISTANCE; INNATE IMMUNITY; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PENICILLIN RESISTANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 3 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SACCHAROMYCES CEREVISIAE; STAPHYLOCOCCUS INFECTION; STAPHYLOCOCCUS SCIURI; WOUND HEALING;

EID: 84856460625     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212799277617     Document Type: Review

References (156)

1. Thomson CJ, Power E, Ruebsamen-Waigmann H, Labischinski H. Antibacterial research and development in the 21(st) Century-an industry perspective of the challenges. Curr Opin Microbiol 2004; 7: 445-50.
2. Spellberg B. Antibiotic Resistance: Promoting Critically Needed Antibiotic Research and Development and Appropriate Use ("Stewardship") of these Precious Drugs. Infectious Diseases Society of America (IDSA) 2010.
3. Donadio S, Maffioli S, Monciardini P, Sosio M, Jabes D. Antibiotic discovery in the twenty-first century: current trends and future perspectives. J Antibiot (Tokyo) 2010; 63: 423-30.
4. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE, Jr. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004; 38: 1279-86.
5. Sellers LJ. Big pharma bails on anti-infectives research. Pharmaceutical Executive 2003.
6. Projan SJ. Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 2003; 6: 427-30.
7. Nathan C. Antibiotics at the crossroads. Nature 2004; 431: 899-902.
8. Steinstraesser L, Kraneburg U, Jacobsen F, Al-Benna S. Host defense peptides and their antimicrobial-immunomodulatory duality. Immunobiology 2011; 216: 322-33.
9. Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol 2009; 30: 131-41.
10. Giamarellou H, Poulakou G. Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs 2009; 69: 1879-901.
11. Nikaido H. Multidrug resistance in bacteria. Annu Rev Biochem 2009; 78: 119-46.
12. de Lencastre H, Oliveira D, Tomasz A. Antibiotic resistant Staphylococcus aureus: a paradigm of adaptive power. Curr Opin Microbiol 2007; 10: 428-35.
13. Rossolini GM, Mantengoli E, Montagnani F, Pollini S. Epidemiology and clinical relevance of microbial resistance determinants versus anti-Gram-positive agents. Curr Opin Microbiol 2010; 13: 582-8.
14. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32: 470-85.
15. Hooper DC. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis 2000; 31 Suppl 2: S24-S28.
16. Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis 2006; 42 Suppl 1: S25-34.
17. Spratt BG. Resistance to antibiotics mediated by target alterations. Science. 1994; 264: 388-93.
18. Kuroda M, Ohta T, Uchiyama I, et al. Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet 2001; 357: 1225-40.
19. Bush K. Alarming beta-lactamase-mediated resistance in multidrugresistant Enterobacteriaceae. Curr Opin Microbiol 2010; 13: 558-64.
20. Levy SB. Active efflux mechanisms for antimicrobial resistance. Antimicrob Agents Chemother. 1992; 36: 695-703.
21. Harder KJ, Nikaido H, Matsuhashi M. Mutants of Escherichia coli that are resistant to certain beta-lactam compounds lack the ompF porin. Antimicrob Agents Chemother. 1981; 20: 549-52.
22. Mor A. Multifunctional host defense peptides: antiparasitic activities. FEBS J 2009; 276: 6474-82.
23. Perrin L, Telenti A. HIV treatment failure: testing for HIV resistance in clinical practice. Science. 1998; 280: 1871-3.
24. Matejuk A, Leng Q, Begum MD, et al. Peptide-based Antifungal Therapies against Emerging Infections. Drugs Future 2010; 35: 197.
25. Prasad R, Kapoor K. Multidrug resistance in yeast Candida. Int Rev Cytol 2005; 242: 215-48.
26. French GL. The continuing crisis in antibiotic resistance. Int J Antimicrob Agents 2010; 36 Suppl 3: S3-7.
27. Hancock REW, Diamond G. The role of cationic antimicrobial peptides in innate host defences. Trends in Microbiology 2000; 8: 402-10.
28. Hancock RE, Rozek A. Role of membranes in the activities of antimicrobial cationic peptides. FEMS Microbiol Lett 2002; 206: 143-9.
29. Guani-Guerra E, Santos-Mendoza T, Lugo-Reyes SO, Teran LM. Antimicrobial peptides: general overview and clinical implications in human health and disease. Clin Immunol 2010; 135: 1-11.
30. Wu Z, Hoover DM, Yang D, et al. Engineering disulfide bridges to dissect antimicrobial and chemotactic activities of human - defensin 3 Proc Natl Acad Sci USA 2003; 100: 8880-5.
31. Circo R, Skerlavaj B, Gennaro R, Amoroso A, Zanetti M. Structural and functional characterization of hBD-1(Ser35), a peptide deduced from a DEFB1 polymorphism. Biochem Biophys Res Commun 2002; 293: 586-92.
32. Kluver E, Schulz-Maronde S, Scheid S, et al. Structure-activity relation of human beta-defensin 3: influence of disulfide bonds and cysteine substitution on antimicrobial activity and cytotoxicity. Biochemistry 2005; 44: 9804-16.
33. Taylor K, Barran PE, Dorin JR. Structure-activity relationships in beta-defensin peptides. Biopolymers 2008; 90: 1-7.
34. Matsuzaki K, Sugishita K, Harada M, Fujii N, Miyajima K. Interactions of an antimicrobial peptide, magainin 2, with outer and inner membranes of Gram-negative bacteria. Biochim Biophys Acta. 1997; 1327: 119-30.
35. Schroeder BO, Wu Z, Nuding S, et al. Reduction of disulphide bonds unmasks potent antimicrobial activity of human betadefensin 1. Nature 469: 419-23.
36. Wang G. Structures of human host defense cathelicidin LL-37 and its smallest antimicrobial peptide KR-12 in lipid micelles. J Biol Chem 2008; 283: 32637-43.
37. Ciornei CD, Sigurdardottir T, Schmidtchen A, Bodelsson M. Antimicrobial and Chemoattractant Activity, Lipopolysaccharide Neutralization, Cytotoxicity, and Inhibition by Serum of Analogs of Human Cathelicidin LL-37. Antimicrob Agents Chemother 2005; 49: 2845-50.
38. Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock REW. The Human Antimicrobial Peptide LL-37 Is a Multifunctional Modulator of Innate Immune Responses. The Journal of Immunology 2002; 169: 3883-91.
39. Bara Å, Ska-Rybak W, Sonesson A, Nowicki R, Schmidtchen A. Glycosaminoglycans inhibit the antibacterial activity of LL-37 in biological fluids. Journal of Antimicrobial Chemotherapy 2006; 57: 260-5.
40. Cherkasov A, Hilpert K, Jenssen H, et al. Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic-resistant superbugs. ACS Chem Biol 2009; 4: 65-74.
41. Braff MH, Hawkins MA, Di Nardo A, et al. Structure-function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immunostimulatory activities. J Immunol 2005; 174: 4271-8.
42. Oren Z, Lerman JC, Gudmundsson GH, Agerberth B, Shai Y. Structure and organization of the human antimicrobial peptide LL- 37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity. Biochem J. 1999; 341(Pt 3): 501-13.
43. Nijnik A, Madera L, Ma S, et al. Synthetic cationic peptide IDR- 1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment. J Immunol 184: 2539-50.
44. Wieczorek M, Jenssen H, Kindrachuk J, et al. Structural studies of a peptide with immune modulating and direct antimicrobial activity. Chem Biol. 17: 970-80.
45. Fischer PM, Zhelev NZ, Wang S, et al. Structure-activity relationship of truncated and substituted analogues of the intracellular delivery vector Penetratin. J Pept Res 2000; 55: 163-72.
46. Yu HB, Kielczewska A, Rozek A, et al. Sequestosome-1/p62 Is the Key Intracellular Target of Innate Defense Regulator Peptide. Journal of Biological Chemistry 2009; 284: 36007-11.
47. Hale JD, Hancock RE. Alternative mechanisms of action of cationic antimicrobial peptides on bacteria. Expert Rev Anti Infect Ther 2007; 5: 951-9.
48. Mookherjee N, Wilson HL, Doria S, et al. Bovine and human cathelicidin cationic host defense peptides similarly suppress transcriptional responses to bacterial lipopolysaccharide. J Leukoc Biol 2006; 80: 1563-74.
49. Bowdish DM, Davidson DJ, Lau YE, et al. Impact of LL-37 on anti-infective immunity. J Leukoc Biol 2005; 77: 451-9.
50. Hancock RE. Peptide antibiotics. Lancet. 1997; 349: 418-22.
51. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 2005; 3: 238-50.
52. Wu M, Maier E, Benz R, Hancock RE. Mechanism of interaction of different classes of cationic antimicrobial peptides with planar bilayers and with the cytoplasmic membrane of Escherichia coli. Biochemistry. 1999; 38: 7235-42.
53. Wu M, Hancock RE. Interaction of the cyclic antimicrobial cationic peptide bactenecin with the outer and cytoplasmic membrane. J Biol Chem. 1999; 274: 29-35.
54. Matsuzaki K, Murase O, Fujii N, Miyajima K. An antimicrobial peptide, magainin 2, induced rapid flip-flop of phospholipids coupled with pore formation and peptide translocation. Biochemistry. 1996; 35: 11361-8.
55. Sass V, Schneider T, Wilmes M, et al. Human beta-defensin 3 inhibits cell wall biosynthesis in Staphylococci. Infect Immun. 78: 2793-800.
56. Spindler EC, Hale JD, Giddings TH, Jr., Hancock RE, Gill RT. Deciphering the mode of action of the synthetic antimicrobial peptide Bac8c. Antimicrob Agents Chemother. 55: 1706-16.
57. Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 2006; 24: 1551-7.
58. R.E.W. H. Introduction to the Theme: Seeking Clarity for Membrane-active Peptides. In: M.A.R C, editor. Membrane-active peptides: Methods and Results on Structure and Function: International University Line; 2010. p. 692.
59. Schneider T, Kruse T, Wimmer R, et al. Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II. Science 2010; 328: 1168-72.
60. Park CB, Kim HS, Kim SC. Mechanism of action of the antimicrobial peptide buforin II: buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem Biophys Res Commun. 1998; 244: 253-7.
61. Kragol G, Lovas S, Varadi G, et al. The antibacterial peptide pyrrhocoricin inhibits the ATPase actions of DnaK and prevents chaperone-assisted protein folding. Biochemistry 2001; 40: 3016-26.
62. Hoiby N, Krogh Johansen H, Moser C, et al. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect 2001; 3: 23-35.
63. Drenkard E, Ausubel FM. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002; 416: 740-3.
64. Overhage J, Campisano A, Bains M, et al. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect Immun 2008; 76: 4176-82.
65. Hell E, Giske CG, Nelson A, Romling U, Marchini G. Human cathelicidin peptide LL37 inhibits both attachment capability and biofilm formation of Staphylococcus epidermidis. Lett Appl Microbiol 2010; 50: 211-5.
66. Jenssen H, Hamill P, Hancock REW. Peptide Antimicrobial Agents. Clin Microbiol Rev 2006; 19: 491-511.
67. Lorin C, Saidi H, Belaid A, et al. The antimicrobial peptide dermaseptin S4 inhibits HIV-1 infectivity in vitro. Virology 2005; 334: 264-75.
68. Shieh MT, WuDunn D, Montgomery RI, Esko JD, Spear PG. Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans. J Cell Biol. 1992; 116: 1273-81.
69. Spillmann D. Heparan sulfate: anchor for viral intruders? Biochimie 2001; 83: 811-7.
70. Sinha S, Cheshenko N, Lehrer RI, Herold BC. NP-1, a rabbit alphadefensin, prevents the entry and intercellular spread of herpes simplex virus type 2. Antimicrob Agents Chemother 2003; 47: 494-500.
71. Tamamura H, Otaka A, Murakami T, et al. Interaction of an anti- HIV peptide, T22, with gp120 and CD4. Biochem Biophys Res Commun. 1996; 219: 555-9.
72. Tamamura H, Xu Y, Hattori T, et al. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun. 1998; 253: 877-82.
73. Horne WS, Wiethoff CM, Cui C, et al. Antiviral cyclic D,L-alphapeptides: targeting a general biochemical pathway in virus infections. Bioorg Med Chem 2005; 13: 5145-53.
74. Haukland HH, Ulvatne H, Sandvik K, Vorland LH. The antimicrobial peptides lactoferricin B and magainin 2 cross over the bacterial cytoplasmic membrane and reside in the cytoplasm. FEBS Lett 2001; 508: 389-93.
75. Lau YE, Rozek A, Scott MG, et al. Interaction and cellular localization of the human host defense peptide LL-37 with lung epithelial cells. Infect Immun 2005; 73: 583-91.
76. Gwadz RW, Kaslow D, Lee JY, et al. Effects of magainins and cecropins on the sporogonic development of malaria parasites in mosquitoes. Infect Immun. 1989; 57: 2628-33.
77. Zasloff M. Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci USA. 1987; 84: 5449-53.
78. Park Y, Jang SH, Lee DG, Hahm KS. Antinematodal effect of antimicrobial peptide, PMAP-23, isolated from porcine myeloid against Caenorhabditis elegans. J Pept Sci 2004; 10: 304-11.
79. Alberola J, Rodriguez A, Francino O, et al. Safety and efficacy of antimicrobial peptides against naturally acquired leishmaniasis. Antimicrob Agents Chemother 2004; 48: 641-3.
80. Efron L, Dagan A, Gaidukov L, Ginsburg H, Mor A. Direct interaction of dermaseptin S4 aminoheptanoyl derivative with intraerythrocytic malaria parasite leading to increased specific antiparasitic activity in culture. J Biol Chem 2002; 277: 24067-72.
81. Rivas L, Luque-Ortega JR, Andreu D. Amphibian antimicrobial peptides and Protozoa: lessons from parasites. Biochim Biophys Acta 2009; 1788: 1570-81.
82. Epand RM, Epand RF. Lipid domains in bacterial membranes and the action of antimicrobial agents. Biochim Biophys Acta 2009; 1788: 289-94.
83. Rotem S, Mor A. Antimicrobial peptide mimics for improved therapeutic properties. Biochim Biophys Acta 2009; 1788: 1582-92.
84. Moerman L, Bosteels S, Noppe W, et al. Antibacterial and antifungal properties of alpha-helical, cationic peptides in the venom of scorpions from southern Africa. Eur J Biochem 2002; 269: 4799-810.
85. Koo JC, Lee B, Young ME, et al. Pn-AMP1, a plant defense protein, induces actin depolarization in yeasts. Plant Cell Physiol 2004; 45: 1669-80.
86. Kim DH, Lee DG, Kim KL, Lee Y. Internalization of tenecin 3 by a fungal cellular process is essential for its fungicidal effect on Candida albicans. Eur J Biochem 2001; 268: 4449-58.
87. Yang D, Chertov O, Oppenheim JJ. The role of mammalian antimicrobial peptides and proteins in awakening of innate host defenses and adaptive immunity. Cellular and Molecular Life Sciences 2001; 58: 978-89.
88. Durr M, Peschel A. Chemokines Meet Defensins: the Merging Concepts of Chemoattractants and Antimicrobial Peptides in Host Defense. Infect Immun 2002; 70: 6515-7.
89. Tjabringaa GS, Ninabera DK, Drijfhoutb JW, Rabea KF, Hiemstraa PS. Human Cathelicidin LL-37 Is a Chemoattractant for Eosinophils and Neutrophils That Acts via Formyl-Peptide Receptors. Int Arch Allergy Immunol 2006; 140: 103-12.
90. Easton DM, Nijnik A, Mayer ML, Hancock REW. Potential of immunomodulatory host defense peptides as novel anti-infectives. Trends in Biotechnology 2009; 27: 582-90.
91. Khine AA, Del Sorbo L, Vaschetto R, et al. Human neutrophil peptides induce interleukin-8 production through the P2Y6 signaling pathway. Blood 2006; 107: 2936-42.
92. Mookherjee N, Hancock R. Cationic host defence peptides: Innate immune regulatory peptides as a novel approach for treating infections. Cellular and Molecular Life Sciences 2007; 64: 922-33.
93. Wieczorek M, Jenssen H, Kindrachuk J, et al. Structural Studies of a Peptide with Immune Modulating and Direct Antimicrobial Activity. Chemistry & Biology 2010; 17: 970-80.
94. Scott M, Dullaghan E, Mookherjee N, et al. An anti-infective peptide that selectively modulates the innate immune response. Nat Biotechnol 2007; 25: 465-72.
95. Nijnik A, Madera L, Ma S, et al. Synthetic Cationic Peptide IDR- 1002 Provides Protection against Bacterial Infections through Chemokine Induction and Enhanced Leukocyte Recruitment. The Journal of Immunology 2010; 184: 2539-50.
96. Opal SM. New perspectives on immunomodulatory therapy for bacteraemia and sepsis. International Journal of Antimicrobial Agents 2010; 36: S70-S3.
97. Lepper, Held, Schneider, et al. Clinical implications of antibioticinduced endotoxin release in septic shock. Intensive Care Medicine 2002; 28: 824-33.
98. Nagaoka I, Hirota S, Niyonsaba FO, et al. Cathelicidin Family of Antibacterial Peptides CAP18 and CAP11 Inhibit the Expression of TNF-α by Blocking the Binding of LPS to CD14+ Cells. The Journal of Immunology 2001; 167: 3329-38.
99. Scott MG, Vreugdenhil AC, Buurman WA, Hancock RE, Gold MR. Cutting edge: cationic antimicrobial peptides block the binding of lipopolysaccharide (LPS) to LPS binding protein. J Immunol 2000; 164: 549-53.
100. Bowdish D, Hancock R. Anti-endotoxin properties of cationic host defence peptides and proteins. J endotoxin Res 2005; 11: 230-6.
101. Davidson DJ, Currie AJ, Reid GSD, et al. The Cationic Antimicrobial Peptide LL-37 Modulates Dendritic Cell Differentiation and Dendritic Cell-Induced T Cell Polarization. J Immunol 2004; 172: 1146-56.
102. van der Does AM, Bogaards SJP, Ravensbergen B, et al. Antimicrobial Peptide hLF1-11 Directs Granulocyte-Macrophage Colony- Stimulating Factor-Driven Monocyte Differentiation toward Macrophages with Enhanced Recognition and Clearance of Pathogens. Antimicrob Agents Chemother 2010; 54: 811-6.
103. Brown KL, Poon GFT, Birkenhead D, et al. Host Defense Peptide LL-37 Selectively Reduces Proinflammatory Macrophage Responses. The Journal of Immunology 2011; 186: 5497-505.
104. Wu WKK, Wong CCM, Li ZJ, et al. Cathelicidins in inflammation and tissue repair: Potential therapeutic applications for gastrointestinal disorders. Acta Pharmacol Sin 2010; 31: 1118-22.
105. Shaykhiev R, Beißwenger C, KÃndler K et al. Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure. American Journal of Physiology - Lung Cellular and Molecular Physiology 2005; 289: L842-L8.
106. Varoga D, Pufe T, Harder J, et al. Human -defensin 3 mediates tissue remodeling processes in articular cartilage by increasing levels of metalloproteinases and reducing levels of their endogenous inhibitors. Arthritis & Rheumatism 2005; 52: 1736-45.
107. Heilborn JD, Nilsson MF, Kratz G, et al. The Cathelicidin Anti- Microbial Peptide LL-37 is Involved in Re-Epithelialization of Human Skin Wounds and is Lacking in Chronic Ulcer Epithelium. J Investig Dermatol 2003; 120: 379-89.
108. Koczulla R, von Degenfeld G, Kupatt C, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. The Journal of Clinical Investigation 2003; 111: 1665-72.
109. Nicholls EF, Madera L, Hancock REW. Immunomodulators as adjuvants for vaccines and antimicrobial therapy. Annals of the New York Academy of Sciences. 1213: 46-61.
110. Davidson DJ, Currie AJ, Reid GSD, et al. The Cationic Antimicrobial Peptide LL-37 Modulates Dendritic Cell Differentiation and Dendritic Cell-Induced T Cell Polarization. The Journal of Immunology 2004; 172: 1146-56.
111. Tomasinsig L, Pizzirani C, Skerlavaj B, et al. The human cathelicidin LL-37 modulates the activities of the P2X7 receptor in a structure-dependent manner. J Bio Chem 2008; 283: 30471-81.
112. Coffelt S, Tomchuck S, Zwezdaryk K, Danka E, Scandurro A. Leucine leucine-37 uses formyl peptide receptor-like 1 to activate signal transduction pathways, stimulate oncogenic gene expression, and enhance the invasiveness of ovarian cancer cells. Mol Cancer Res 2009; 7: 907-15.
113. Mookherjee N, Lippert DND, Hamill P, et al. Intracellular Receptor for Human Host Defense Peptide LL-37 in Monocytes. J Immunol 2009; 183: 2688-96.
114. Mookherjee N, Brown K, Bowdish D, et al. Modulation of the Tolllike receptor-mediated inflammatory response by the endogenous human host defence peptide LL-37. J Immunol 2006; 176: 2455-64.
115. Moser C, Weiner DJ, Lysenko E, et al. {beta}-Defensin 1 Contributes to Pulmonary Innate Immunity in Mice. Infect Immun 2002; 70: 3068-72.
116. Pütsep K, Carlsson G, Boman HG, Andersson M. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. The Lancet 2002; 360: 1144-9.
117. Limura M, Gallo RL, Hase K, et al. Cathelicidin Mediates Innate Intestinal Defense against Colonization with Epithelial Adherent Bacterial Pathogens. J Immunol 2005; 174: 4901-7.
118. Huang LC, Reins RY, Gallo RL, McDermott AM. Cathelicidindeficient (Cnlp -/-) mice show increased susceptibility to Pseudomonas aeruginosa keratitis. Invest Ophthalmol Vis Sci 2007; 48: 4498-508.
119. WHO. World Health Statistics on http://www.who.int/whosis/whostat/2009/en/index.html 2009.
120. Scott MG, Rosenberger CM, Gold MR, Finlay BB, Hancock REW. An {alpha}-Helical Cationic Antimicrobial Peptide Selectively Modulates Macrophage Responses to Lipopolysaccharide and Directly Alters Macrophage Gene Expression. J Immunol 2000; 165: 3358-65.
121. Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock RE. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol 2002; 169: 3883-91.
122. Lipsky BA, Holroyd KJ, Zasloff M. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin Infect Dis 2008; 47: 1537-45.
123. Brzoska T, Luger TA, Maaser C, Abels C, Bohm M. Alphamelanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev 2008; 29: 581-602.
124. Spadaro M, Caorsi C, Ceruti P, et al. Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells. FASEB J 2008; 22: 2747-57.
125. de la Rosa G, Yang D, Tewary P, Varadhachary A, Oppenheim JJ. Lactoferrin acts as an alarmin to promote the recruitment and activation of APCs and antigen-specific immune responses. J Immunol 2008; 180: 6868-76.
126. Spadaro M, Curcio C, Varadhachary A, et al. Requirement for IFNgamma, CD8+ T lymphocytes, and NKT cells in talactoferrininduced inhibition of neu+ tumors. Cancer Res 2007; 67: 6425-32.
127. Jung S, Dingley AJ, Augustin R, et al. Hydramacin-1, structure and antibacterial activity of a protein from the basal metazoan Hydra. J Biol Chem 2009; 284: 1896-905.
128. Augustin R, Anton-Erxleben F, Jungnickel S, et al. Activity of the novel peptide arminin against multiresistant human pathogens shows the considerable potential of phylogenetically ancient organisms as drug sources. Antimicrob Agents Chemother 2009; 53: 5245-50.
129. Fjell CD, Jenssen HV, Hilpert K, et al. Identification of Novel Antibacterial Peptides by Chemoinformatics and Machine Learningâ Journal of Medicinal Chemistry 2009; 52: 2006-15.
130. Jerala R. Synthetic lipopeptides: a novel class of anti-infectives. Expert Opin Investig Drugs 2007; 16: 1159-69.
131. Hornef MW, Putsep K, Karlsson J, Refai E, Andersson M. Increased diversity of intestinal antimicrobial peptides by covalent dimer formation. Nat Immunol 2004; 5: 836-43.
132. Giuliani A, Pirri G, Bozzi A, et al. Antimicrobial peptides: natural templates for synthetic membrane-active compounds. Cell Mol Life Sci 2008; 65: 2450-60.
133. Liu L, Xu K, Wang H, et al. Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent. Nat Nanotechnol 2009; 4: 457-63.
134. Avrahami D, Shai Y. Conjugation of a magainin analogue with lipophilic acids controls hydrophobicity, solution assembly, and cell selectivity. Biochemistry 2002; 41: 2254-63.
135. Majerle A, Kidric J, Jerala R. Enhancement of antibacterial and lipopolysaccharide binding activities of a human lactoferrin peptide fragment by the addition of acyl chain. J Antimicrob Chemother 2003; 51: 1159-65.
136. Lockwood NA, Haseman JR, Tirrell MV, Mayo KH. Acylation of SC4 dodecapeptide increases bactericidal potency against Grampositive bacteria, including drug-resistant strains. Biochem J 2004; 378: 93-103.
137. Makovitzki A, Avrahami D, Shai Y. Ultrashort antibacterial and antifungal lipopeptides. Proc Natl Acad Sci USA 2006; 103: 15997-6002.
138. Mygind PH, Fischer RL, Schnorr KM, et al. Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature 2005; 437: 975-80.
139. Bommarius B, Jenssen H, Elliott M, et al. Cost-effective expression and purification of antimicrobial and host defense peptides in Escherichia coli. Peptides 2010; 31: 1957-65.
140. Pini A, Falciani C, Mantengoli E, et al. A novel tetrabranched antimicrobial peptide that neutralizes bacterial lipopolysaccharide and prevents septic shock in vivo. FASEB J 2010; 24: 1015-22.
141. Fischer PM. The design, synthesis and application of stereochemical and directional peptide isomers: a critical review. Curr Protein Pept Sci 2003; 4: 339-56.
142. Kindrachuk J, Scruten E, Attah-Poku S, et al. Stability, toxicity and biological activity of host defense peptide BMAP28 and its inversed and retro-inversed isomers. Biopolymers 2010.
143. Peschel A, Sahl HG. The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat Rev Microbiol 2006; 4: 529-36.
144. Hancock RE. Concerns regarding resistance to self-proteins. Microbiology 2003; 149: 3343-4; discussion 4-5.
145. Bell G, Gouyon PH. Arming the enemy: the evolution of resistance to self-proteins. Microbiology 2003; 149: 1367-75.
146. Fritsche TR, Rhomberg PR, Sader HS, Jones RN. Antimicrobial activity of omiganan pentahydrochloride tested against contemporary bacterial pathogens commonly responsible for catheterassociated infections. J Antimicrob Chemother 2008; 61: 1092-8.
147. Maloy WL, Kari UP. Structure-activity studies on magainins and other host defense peptides. Biopolymers. 1995; 37: 105-22.
148. Chin JN, Jones RN, Sader HS, Savage PB, Rybak MJ. Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa. J Antimicrob Chemother 2008; 61: 365-70.
149. Mosca DA, Hurst MA, So W, et al. IB-367, a protegrin peptide with in vitro and in vivo activities against the microflora associated with oral mucositis. Antimicrob Agents Chemother 2000; 44: 1803-8.
150. van der Does AM, Bogaards SJ, Ravensbergen B, et al. Antimicrobial peptide hLF1-11 directs granulocyte-macrophage colonystimulating factor-driven monocyte differentiation toward macrophages with enhanced recognition and clearance of pathogens. Antimicrob Agents Chemother 2010; 54: 811-6.
151. Urban C, Mariano N, Rahal JJ, et al. Polymyxin B-Resistant Acinetobacter baumannii Clinical Isolate Susceptible to Recombinant BPI and Cecropin P1. Antimicrob Agents Chemother 2001; 45: 994-5.
152. Zhao Z, Ma Y, Dai C, et al. Imcroporin, a new cationic antimicrobial peptide from the venom of the scorpion Isometrus maculates. Antimicrob Agents Chemother 2009; 53: 3472-7.
153. Hernandez-Aponte CA, Silva-Sanchez J, Quintero-Hernandez V, et al. Vejovine, a new antibiotic from the scorpion venom of Vaejovis mexicanus. Toxicon 2011; 57: 84-92.
154. Zhao H, Kong Y, Wang H, et al. A defensin-like antimicrobial peptide from the venoms of spider, Ornithoctonus hainana. J Pept Sci 2011.
155. Uccelletti D, Zanni E, Marcellini L, et al. Anti-Pseudomonas activity of frog skin antimicrobial peptides in a Caenorhabditis elegans infection model: a plausible mode of action in vitro and in vivo. Antimicrob Agents Chemother 2010; 54: 3853-60.
156. Mangoni ML, Maisetta G, Di Luca M, et al. Comparative analysis of the bactericidal activities of amphibian peptide analogues against multidrug-resistant nosocomial bacterial strains. Antimicrob Agents Chemother 2008; 52: 85-91.